Loading patent…
AssigneeShandong Boan Biotechnology Co., Ltd.
InventorsLi Zhou, Avanish Varshney, Deyong Song, Chuangchuang Dong, Ninghai Wang
Estimating the term…
The present application provides CLDN18.2 antibodies or antigen binding fragments thereof and related CLDN18.2/CD3 bispecific antibodies, as well as corresponding nucleic acids encoding same, vectors comprising such nucleic acids, host cells transfected with such nucleic acids or vectors. The present application further relates to isolated CLDN18.2 antibodies or antigen binding fragments thereof and related CLDN18.2/CD3 bispecific antibodies, pharmaceutical compositions comprising such antibodies, antigen binding fragments, bispecific antibodies, nucleic acids, vectors, or host cells and optionally a pharmaceutically acceptable carrier, and methods of treating cancer in a subject in need thereof by administering such pharmaceutical compositions. The cancers treated in accordance with the present application include CLDN18.2-positive cancers, such as, inter alia, gastric cancer and pancreatic cancer.
An anti-CLDN18.2 antibody or antigen binding fragment thereof, comprising a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region comprises HCDR1 comprising the amino acid sequence of SEQ ID NO. 11, HCDR2 comprising the amino acid sequence of SEQ ID NO. 12 and HCDR3 comprising the amino acid sequence of SEQ ID NO. 13, and the light chain variable region comprises LCDR1 comprising the amino acid sequence of SEQ ID NO. 14, LCDR2 comprising the amino acid sequence of SEQ ID NO. 15 and LCDR3 comprising the amino acid sequence of SEQ ID NO. 16.
Dependencies are inferred from the claim text.